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PU.1 is a tissue-specific transcription factor that is expressed in cells of the hematopoietic lineage 
including macrophages, granulocytes, and B lymphocytes. Bone marrow-derived macrophages 
transfected with an antisense PU.1  expression construct or treated with antisense oligonucle- 
otides showed a decrease in proliferation compared with controls.  In contrast, bone marrow 
macrophages transfected with a sense PU. 1 expression construct  displayed enhanced  macro- 
phage colony-stimulating factor (M-CSF)-dependent proliferation. Interestingly, there was no 
effect of sense or antisense constructs of PU.1  on the proliferation of the M-CSF-independent 
cell line, suggesting that the response was M-CSF dependent.  This was further supported by 
the finding that macrophages transfected with a sense or an antisense PU. 1 construct showed, 
respectively, an increased or a reduced level of surface expression of receptors for M-CSF. The 
enhancement of proliferation seems to be selective for PU.1,  since transfections with several 
other members of the ets family, including ets-2 and fli-1, had no effect. Various mutants of 
PU.1  were also tested for their ability to affect macrophage proliferation. A reduction in mac- 
rophage proliferation was  found  when  cells  were  transfected with  a  construct  in  which  the 
DNA-binding domain of PU.1  was  expressed.  The PEST  (proline-,  glutamic acid-,  serine-, 
and threonine-rich region)  sequence of the PU.1  protein, which is an important domain for 
protein-protein  interactions  in  B  cells,  was found  to  have  no  influence  on PU.l-enhanced 
macrophage proliferation when an expression construct containing PU. 1 minus the PEST do- 
main was transfected into bone marrow-derived macrophages. In vivo, PU. 1 is phosphorylated 
on several serine residues. The transfection ofplasmids containing PU. 1 with mutations at each 
of five serines showed that only positions 41  and 45 are critical for enhanced macrophage pro- 
liferation. We conclude that PU. 1 is necessary for the M-CSF-dependent proliferation of mac- 
rophages.  One  of the  proliferation-relevant  targets  of this  transcription  factor could  be  the 
M-CSF receptor. 
M  ononuclear  phagocytes  represent  a  large  family  of 
.cell types that includes  tissue macrophages, Kupffer 
cells  (liver),  Langerhans  cells  (dermis),  osteoclasts  (bone), 
microglia  (brain),  and perhaps some of the  interdigitating 
and follicular dendritic cells found in lymphoid organs (1). 
Macrophages originate from undifferentiated stem cells and 
require  specific  growth  factors  called  colony-stimulating 
factors (IL-3, M-CSF,  and GM-CSF)  for their generation 
(2).  The receptor for the growth factor M-CSF,  the prod- 
uct of the c-fins gene, has been well characterized (3).  The 
binding of M-CSF to its  receptor induces receptor kinase 
activity and  triggers  a  cascade  of biochemical events  that 
leads  to  the  expression  of M-CSF-responsive  genes  and 
subsequent cell proliferation. 
Recently, we cloned a tissue-specific DNA-binding pro- 
tein,  called PU.1,  that  is an activator of transcription  (4). 
This protein is expressed in macrophages, granulocytes, mast 
cells,  osteoclasts, and B  lymphocytes (5).  PU. 1 binds  to  a 
purine-rich sequence that contains a central core with the 
sequence  5'-GGAA-3'  (4).  The  DNA-binding  domain, 
which is located near the COOH  terminus, has significant 
sequence  identity  with  the  DNA-binding  domain  that  is 
present  in  the  Ets  family  of DNA-binding  proteins  (4). 
PU.1  is  the  product  of the  putative  oncogene  Spi-1  (6), 
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the insertion of spleen focus-forming virus (SFFV) (7). 
Some of the genes thought  to be regulated by PU.1  in 
lymphocytes include the Ig K light chain gene 3' enhancer 
(8, 9), the Ig k  2-4 enhancer (10), the Ig heavy chain p, en- 
hancer  (11),  the IgJ chain gene  (12),  and the rob-1  gene, 
which is expressed in early B  cell differentiation (13,  14). 
PU. 1 is believed to regulate the expression in macrophages 
of several receptors, which include the Fc',/RI~ gene  (15), 
the  Fc~/PdlIA gene  (16),  the M-CSF receptor gene  (17), 
the CD11b  gene (18,  19), the scavenger receptor (20), the 
macrophage inflammatory protein lc~ (MIP-lo  0  (21), IL-113 
(22),  and  CD18  (23).  Recently,  it  has  been  shown  that 
PU.1  interacts  with  the  B  cell--specific factor  NF-EM5 
(Pip) and stimulates transcription from the Ig K 3' enhancer 
(7, 24). 
Using  the  technique  of gene  targeting,  mice  homozy- 
gous for the disruption of the PU.1  gene have been gener- 
ated.  Scott et al.  (25)  have reported the absence of homo- 
zygous mutant progeny, suggesting that disruption of PU. 1 
results in  embryonic lethality. More  recently, McKercher 
et al. (McKercher, S., B. Torbett, K. Anderson, D. Vestal, 
G. Henkel, C. Paige, and R.A. Mald, manuscript in prepa- 
ration) have obtained mice homozygous for the disruption 
of the PU.1  gene  that were born and survived for up to 
2 wk when treated with the appropriate antibiotic. Neither 
macrophages  nor B  cells were  present  in  either  example, 
suggesting  that  PU.1  is  involved  in  the  development  of 
these cells. Using PU. 1 -/-  ES cells differentiated in vitro, 
Olson  et al.  (26)  concluded that  PU.1  is not  essential for 
early myeloid gene expression, but is required for terminal 
myeloid differentiation. 
In  the  present  study  we  demonstrate  that  PU.1  is  in- 
volved in macrophage proliferation. Transfection of a PU. 1 
expression construct  into  bone  marrow  macrophages  was 
found to stimulate both M- and GM-CSF-dependent pro- 
liferation of these cells, whereas transfection ofa PU.1  anti- 
sense construct or a construct that expressed DNA-binding 
domain of PU.1 into bone marrow macrophages was found 
to  inhibit  the  proliferative  effect  of the  growth  factors. 
Thus,  PU.1  seems to  regulate the expression of genes in- 
volved within macrophage proliferation. 
Materials  and Methods 
Mouse Bone Marrow-derived Macrophages.  Macrophages  derived 
from  bone  marrow  cultures  (BMDM) 1 were  obtained  as  de- 
scribed (27).  6-wk-old DBA/2  mice  (The Jackson Laboratory, 
Bar Harbor, ME) were killed by cervical dislocation, and both fe- 
murs were dissected free of adherent tissue. The ends of the bones 
were cut off and the marrow tissue was eluted by irrigation with 
PBS. Cells were suspended by vigorous pipetting, washed once in 
PBS, and collected by centrifugation. We cultured 107 cells in a 
plastic,  nontissue  culture,  150-ram  petri  dish  (Lab-Tek  4030; 
1Abbreviations used in this paper: BMDM,  bone marrow-derived  macro- 
phages; LCM, L cell-conditioned medium; PEST, proline (P), glutamic 
acid (E), serine (S), and threonine (T). 
Miles Laboratories, Inc., Naperville, IL) in 50 ml of DME con- 
taining 2 mM L-glutamine, 1 mM Na pyruvate, 50 U/ml penicil- 
lin, 50 mg/ml streptomycin, 20%  FCS, and 30%  L  cell-condi- 
tioned medium (LCM) as a source of  M-CSF. The cell suspensions 
were  incubated at  37~  in  a  humidified 5%  C02  atmosphere. 
Macrophages were loosely adherent to the dishes and were har- 
vested with cold PBS.  In some experiments, serum-free media 
composed of CMRL-1066, insulin, glutamine, transferrin  (GIBCO 
BILL, Gaithersburg, MD), and sodium bicarbonate, were used. 
Cultured Cell D'nes.  The mufine fibrosarcoma L929 and the mu- 
rine macrophage cell fines RAW264.7, IC-21, and BAC1 2F5-A 
were maintained in DME supplemented with 2 mM L-glutamine, 
50 U/ml penicillin, 50 mg/ml streptomycin, 1 mM Na pyruvate, 
and 5% FCS. 
Proliferation Assay.  Cell proliferation was  measured as previ- 
ously described (28) with minor modifications. After electropora- 
tion, cells  (5  ￿  10  s)  were incubated for 24  h  in 24-well plates 
(3424 MARK II; Costar Corp., Cambridge, MA) in 1 ml of me- 
dia with the indicated growth factor. For the experiments with 
oligodeoxynucleotides, 5  ￿  104 BMDM were incubated in 96- 
well plates with 100 ml of media containing M-CSF for 2 h. Me- 
dia were aspirated and replaced by 0.2  ml of media containing 
[3H]thymidine (1.0  mCi/ml). After an additional 2 h  of incuba- 
tion at 37~  media were removed and cells were fLxed in metha- 
nol. After three washes in 10% TCA, cells were solubilized in 1% 
SDS and 0.3 M NaOH. Radioactivity was counted by liquid scin- 
tillation. All samples were prepared in triplicate and the results are 
expressed as  the  mean  value.  In  some  experiments,  cells  were 
trypsinized and counted with a Coulter counter (ZM model; Hi- 
aleah, FL). Each experiment was performed at least five times and 
the  results are expressed as the mean  +  SD.  Statistical analyses 
were performed using the Student's paired t test, comparing the 
results of at least five independent experiments. 
Transfections.  Cells  were  removed  from  plates  and  washed 
twice in serum-free media. Cells were then incubated (12  3<  10 ~' 
in 1 ml of serum-free media) at 4~  in the cuvettes used for elec- 
troporation, with 2 p~g of DNA for 15 rain. Electroporation was 
carried out using a BTX  electroporator (Transfector  100;  Bio- 
technologies & Exp. Research, San Diego, CA). Cells were incu- 
bated for a further 15 rain on ice before they were distributed in 
24-well plates. To determine the transfection efficiency in some 
experiments, we  transfected an  expression construct  containing 
the  green fluorescent protein gene  (Clontech,  Palo Alto, CA). 
After 2 d of culture, cells were fixed, stained, and counted (29). 
In a series of preliminary experiments, we tested the appropri- 
ate conditions for transfection using the electroporation method 
(10 ms at 200 mV). We also found that increasing the amount of 
DNA transfected (any type) in BMDM resulted in a concentra- 
tion-dependent decrease  in  proliferation. Therefore,  we  chose 
conditions that optimized the number of cells transfected, but also 
permitted proliferation. The amount of DNA used was 2 mg for 
12 ￿  106 cells, which resulted in 7-12% of cells being transfected, 
as assessed by staining for green fluorescent protein. 
Plasmids and Oligodeoxynucleotides.  The PU.1  expression vec- 
tor, PUpECE,  was  constructed by ligating the full-length PU.1 
cDNA into the EcoR1 site of the expression vector, pECE  (30). 
The retinoic acid receptor e/a3 pECE  was  a gift from M.  Pfahl 
(La Jolla Cancer Research Foundation) (31). The PU.1  antisense 
construction was  made  by inserting the  PU.I  cDNA  into  the 
HindlII -  Sal sites of the pHb APr-l-neo vector in the reverse 
orientation (32). 
The pBluescript KS+  vector was purchased from Stratagene, 
Inc. (La Jolla, CA), and the pBL CAT vector was obtained from 
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were prepared using a DNA synthesizer (Model 380A; Applied 
Biosystems, Inc., Foster City, CA) and purified as described pre- 
viously (34).  The PU.1  antisense (5'-TTTGCACGCCTGTAA- 
CATCCAGCTGACCTC-3')  ohgodeoxynucleotide  synthesized 
for these studies straddled the predicted translation-initiation site 
of the PU. 1 mRNA. A computer-assisted search of the GenBank 
database for mammalian sequences complementary to these anti- 
sense  oligodeoxynucleotides revealed little homology with other 
genes. 
Specific sites in the PU.1 gene were mutagenized using oligo- 
nucleotides spanning the desired site and a nearby unique restric- 
tion site, and generating the new fragment using the polymerase 
chain reaction. DNA fragments were isolated, the fragment was 
inserted into the PU.1  eukaryotic expression plasmid PUpECE 
previously described, and the DNA sequence was determined (8). 
The plasmids containing the DNA-binding domain (170-260) or 
the proline (P),  glutamic acid (E),  serine (S), and threonine  (T) 
rich region (PEST) deletion (126-159) of PU.1 have been previ- 
ously described (8). The plasmids containing ets-2 and fli-1 in the 
pECE vector have been previously described (35). 
Growth Factors and Interleukins.  Recombinant  growth  factors 
were a gift from DNAX (Palo Alto, CA). In some experiments 
we used LCM as a source of M-CSF. The  amount of M-CSF 
present in LCM was determined using a M-CSF standard. The 
growth  activity of LCM  could be  blocked by a  specific mAb 
against M-CSF. The M-CSF blocking antibody was a gift from 
Dr.  H.S.  Lin  (Washington University School of Medicine, St. 
Louis, MO) (36). 
Determination of M-CSF Receptors on the Cell Surface.  The deter- 
ruination of M-CSF receptors on the cell surface was performed 
using specific antibodies and cytoflurometer analysis as previously 
described (37).  Cells were washed three times in PBS and incu- 
bated with an excess of goat IgG (Sigma Chemical Co., St. Louis, 
MO) (250 mg/ml) to block Fc receptors. After 30 rain at 4~  cells 
were washed, the primary antibody (rabbit anti-mouse c-fins; Up- 
state Biotechnology Inc., Lake Placid, NY) was added at a 1/200 
dilution, and cells were incubated for 45 min at 4~  Finally, cells 
were incubated with fluorescein-conjugated goat affinity-purified 
F(ab')2 fragment to rabbit IgG (Cappel, Turhout, Belgium) at a 
dilution of 1/500, as recommended by the supplier, for 30 rain at 
4~  Cytometry  analysis  was  carried  out  using  an  Epics  Ehte 
(Coulter Corp., Hialeah, FL) apparatus. 
Results 
The transcription factor PU. 1 has been hnked to the im- 
mortalization of erythroblasts, and may be involved in the 
regulation of a  number of genes in macrophages, some of 
which are involved in development or growth control. To 
examine  its  role  in  this  latter process,  we  designed both 
antisense and sense expression constructs of PU.1  and trans- 
fected these constructs into BMDM.  The cells were grown 
from bone marrow cells cultured in the presence of M-CSF 
for  5-7  d,  which  promotes  the  prohferation  of macro- 
phages but not other cell types. After 5-7  d,  the BMDM 
were  transfected with  either the PU.1  antisense  construct 
PU.I-pHb  or the pHb vector alone and replated in media 
containing various concentrations of M-CSF. The transfec- 
tion  efficiency was  estimated  to  be  between  7  and  12% 
based on the transfection of a green fluorescent protein ex- 
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Figure  1.  (A) Antisense PU.1  inhibits M-CSF-dependent prolifera- 
tion. BMDM  were transfected with the pECE  or pHb vectors or the 
PU.1 antisense construction. After transfection, cells were incubated for 
24 h in the presence of the indicated concentrations of M-CSF. Thymi- 
dine incorporation was measured and results were expressed as the mean 
+  SD. At concentrations of 600 or 1,200 U/ml of M-CSF, there was a 
significant  difference between controls and antisense values (P <0.01).  (B) 
Antisense oligodeoxynucleotides  inhibit M-CSF-dependent proliferation. 
BMM were incubated with antisense or sense (control) ohgodeoxynucle- 
otides in the presence of the indicated concentrations of M-CSF (U/ml) 
for 24 h, and thymidine incorporation was measured. Values of sense and 
antisense in the presence of the same concentrations of oligonucleotides 
and M-CSF were significantly  different (P <0.01). 
pression construct.  BMDM  transfected with  the  antisense 
PU.1  construct  in  the  presense  of M-CSF  had  a  signifi- 
cantly reduced thymidine incorporation compared with the 
controls in which the vector alone was transfected into the 
cells (Fig. 1 A). The experiment was repeated using an an- 
tisense  oligonucleotide  made  complementary  to  a  region 
that included the initiation codon of PU. 1. A  sense oligo- 
nucleotide to the same region was made as a  control. We 
observed that  the  antisense but  not  the  sense  oligonucle- 
otide inhibited BMDM  thymidine incorporation in a dose- 
dependent  manner  that was  dependent  on  the  concentra- 
tion of M-CSF in the media (Fig. 1 B). 
These results suggested that a block in the expression of 
PU.1  may  inhibit  macrophage  proliferation.  If this  were 
the case, we reasoned that the overexpression of PU. 1 may 
stimulate proliferation. To  test  this  possibility, we  gener- 
ated a sense construct of PU. 1, PU. 1-pECE and proceeded 
to analyze the effect of the overexpression of PU.1  on the 
M-CSF--stimulated proliferation of BMDM.  In  the  pres- 
ence  of M-CSF,  the number  of BMDM  was  significantly 
higher when the BMDM were transfected with PU. 1 com- 
pared with the BMDM that were transfected with the vector 
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Figure  2.  PU.1 enhances M-CSF-dependent proliferation of macro- 
phages. BMDM were tranffected with PU. 1 or the control vector (pECE) 
in the presence (striped  bars) or absence (black  bars) of M-CSF. After an 
overnight incubation, the number of cells was counted using a Coulter 
counter. In the presence of M-CSF, there was a significant  difference  be- 
tween values of transfected cells with the control vector and the PUA 
vector (P <0.01). 
alone (Fig. 2). This result was also confirmed using thymi- 
dine incorporation as an index ofmacrophage proliferation. 
Thymidine incorporation was  higher  in  BMDM  treated 
with  M-CSF  and  transfected  with  the  PU.1  expression 
construct when compared with BMDM treated with M-CSF 
and transfected with vector alone (Fig. 3). 
To determine whether PU.1  acts  as a  general factor  in 
macrophage proliferation, we incubated macrophages trans- 
fected with PU.1 or the control vector (pECE) in the pres- 
ence of several recombinant growth factors or interleukins 
(Fig. 3). We observed an increase in thymidine incorpora- 
tion to  varying degrees  in BMDM  treated  with M-CSF, 
GM-CSF, IL-3,  IL-1,  IL-4, and IL-6 compared with the 
control.  No  difference in thymidine incorporation com- 
pared with controls was found when cells were cultured in 
the presence of either G-CSF or IL-2. When macrophages 
were  transfected with  an  expression construct containing 
PU. 1, a significant increase in thymidine incorporation was 
observed only in cells  treated  with M-CSF or  GM-CSF. 
These data suggest that PU.1  is involved in the regulation 
of macrophage  proliferation that  is  M-CSF  or  GM-CSF 
dependent. 
GM-CSF is known to induce the expression of M-CSF 
(38-41).  To  determine whether the  increase in prolifera- 
tion that we observed with the addition of GM-CSF to the 
cultures was due to the production of M-CSF, we added a 
mAb made against M-CSF to the culture media. The addi- 
tion ofanti-M-CSF antibodies caused a substantial decrease 
(30%) in BMDM proliferation in cells transfected with con- 
trol vector alone. This may be due to the inhibition of the 
autocrine production of M-CSF induced by GM-CSF. We 
observed that in the presence of the mAb against M-CSF 
there was no stimulation ofthymidine incorporation above 
background when GM-CSF was added to the cultures and 
the  PU.1  expression  construct  transfected  into  the  cells 
(Fig. 4). These data suggest that the enhancement of GM- 
CSF-dependent proliferation  in  PU.l-transfected  macro- 
phages  may  be  related  to  the  autocrine  production  of 
M-CSF (38-41). 
The effect of PU. i  on proliferation appears to be linked to 
the growth factor-stimulated proliferation ofM-CSF. PU. 1 
has been shown to bind to the promoter of the M-CSF re- 
ceptor  and therefore  may be  an important factor  for  the 
regulated expression of this receptor  (17,  42).  To  address 
this possibility, we transfected BMDM with a PU. 1 sense, 
antisense construct or vector alone as  a  control and mea- 
sured  the  level of M-CSF receptor  surface  expression by 
flow cytometry. BMDM transfected with the vector alone 
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Figure  3.  PU.1  enhances 
M-CSF- and GM-CSF-depen- 
dent proliferation. BMDM were 
transfected with  PU.I  or  the 
control vector and incubated for 
24 h in the presence of different 
cytokines and  growth factors. 
Thymidine  incorporation  was 
measured as described in Materi- 
als  and  Methods.  Comparing 
cells transfected with the control 
vector and the PU.1 vector, only 
in the  presence of M-CSF and 
GM-CSF, there was a significant 
difference (P <0.0 I). 
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Figure  4.  PU.1  enhances  GM-CSF-dependent  proliferation  and  is 
abolished by mAbs against  M-CSF. BMM were tranfected with PU. 1 or 
the  control vector and incubated for 24  h  in the presence of GM-CSF 
with or without mAbs to M-CSF, and thymidine incorporation was de- 
termined. There was a significant  difference  between the values oftrans- 
fected cells with the control vector and the PU.1  vector in the absence 
(P <0.01) but not in the presence of anti-M-CSF antibodies (P >0.05). 
were found to contain two populations  of cells  expressing 
the M-CSF receptor, one of which presented more recep- 
tors than the other (Fig. 5).  Because these cells were prolif- 
erating, the heterogeneity in the number of M-CSF recep- 
tors may be related to the different stages of the cell cycle. 
The  BMDM  transfected  with  the  sense  PU.1  vector 
showed a  marked  increase  in the  population  of ceils with 
O 
O 
CONTROL 
VECTOR 
the  higher  number  of receptors.  In contrast,  the  BMDM 
transfected with the antisense PU.1  construct showed a re- 
duction of the same cell population (Fig. 6). Similar results 
were  obtained when  antisense  oligonucleotides were used 
(data  not shown).  Thus,  PU.1,  which has been shown to 
bind  the  M-CSF  promoter  and  regulate  expression  from 
this promoter using a reporter construct, is also involved in 
the  regulation  of M-CSF  receptor  expression  in  macro- 
phages in vivo. 
Transfection  of PU.1  into  BMDM  in  the  absence  of 
M-CSF  had  no  effect on  the  proliferation  of the  macro- 
phages, suggesting that the effect of the antisense  and sense 
PU. 1 constructs was growth factor dependent.  We therefore 
wanted to know what effect PU.1  may have on M-CSF- 
independent proliferation.  For this purpose we transfected 
a series of cell lines that are growth factor independent with 
PU. 1 in  the sense  or antisense  orientation.  The prolifera- 
tion  of three  macrophage  cell  lines,  IC-21,  RAW264.7, 
and 2F5A, which express PU.1  endogenously, were tested 
using the  sense  and  antisense  constructs,  and  no  effect on 
proliferation was observed (data not shown). These data sug- 
gest that PU. 1 is involved in a proliferative mechanism that 
is only present in growth factor-dependent macrophages. 
Since  PU.1  belongs  to  a  large  family of related  DNA- 
binding proteins  (Ets family)  (43,  44),  we were  interested 
in determining whether the effect of PU.1  on macrophage 
proliferation  was  specific  for PU.1,  or whether  other Ets 
family members could have the same effect on macrophage 
proliferation.  Expression  constructs of ets-2 and fli-1  were 
generated  to  test  this  possibility.  When  expression  con- 
structs containing either ets-2 or fli-1 were transfected into 
BMDM,  no  increase  in  macrophage  proliferation  above 
that  seen  using  the  vector  alone  was  detected  (Fig.  6). 
Thus, we conclude that the effect of PU. 1 on macrophage 
proliferation is specific for PU.1. 
Previous  work  on  the  PU.1  protein  has  demonstrated 
that  there  are  a  number  of functional  domains.  We were 
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Figure  5.  Effect  of  the  PU.1  vector  and  antisense  construction  on 
M-CSF receptor expression. BMM were transfected  with the vector pHb 
or the vector containing the sense PU.1  or the antisense  construction, and 
incubated for 24 h in the presence of 1,200  U/rrfl of M-CSF. M-CSF re- 
ceptors were determined using specific antibodies and cytometry analysis. 
(Filled area)  Anti-M-CSF-treated cells; (unfilled area) control and second- 
ary antibody but not primary (anti-M-CSF receptor). 
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Figure  6.  PU.1  enhances  M-CSF-dependent  macrophage prolifera- 
tion. BMM were transfected  with PU.1, ets-2,  fli-1, or the control vector. 
Cells were incubated for 24 h in the presence of different  concentrations 
of M-CSF  and  thymidine  incorporation  was  determined.  At  different 
concentrations of M-CSF, there was a significant  difference  between the 
values of transfected  cells with the PU. 1 vector and the control, ets-2, or 
fli-1 vectors (P <0.01). 
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Figure 7.  (A) The DNA-binding domain of PU.1 inhibits M-CSF--dependent  proliferation.  BMDM were transfected with the pECE vector (control) 
or the vector containing  PU.1, the DNA-binding  domain of PU.1, or PU.1 with  a deletion  in the PEST domain.  Cells  were incubated  for 24 h in the pres- 
ence of indicated  concentrations  of M-CSF, and thymidine  incorporation  was measured. At concentrations  of 1,200 U/nil of M-CSF, there was a signif- 
icant difference between the cells transfected with the wild type or the PEST-deleted vectors and the control vector (P <0.01). There was also a signifi- 
cant difference between the cells transfected with the control and the binding site vector (P <0.01). (B) The role of PU.1 phosphorylation  on the 
enhancement  of M-CSF-dependent proliferation.  BMDM were transfected with the pECE vector (control) or the vector containing PU. 1 (wild type)  or 
with the indicated  mutations of the five serines. Cells were incubated for 24 h in the presence of the indicated  amounts of M-CSF. Thymidine incorpo- 
ration was measured and results were expressed as the mean. SD was <7% of the mean  values. (top) A model of PU.1 is presented. At concentrations  of 
1,200 U/ml of M-CSF, there was a significant  difference between cells transfected  with the wild type and the control vectors (P <0.01). However, there 
was no difference  between the wild type and the the $132/133A or the $148A mutations. A difference  was found between the control vector and the 
$45A, the $41A, or the $41/$45A vectors (P <0.01). 
interested in determining if these domains in the PU. 1 pro- 
tein were necessary for the affect of PU. 1 on macrophage 
proliferation. Two  regions of the  PU.1  protein that have 
been demonstrated  to  have  funtional importance are  the 
DNA-binding domain  (amino  acids  170-260)  and  the 
PEST domain (amino acids 126-159). The PEST domain 
has been shown to be important for the interaction ofPU. 1 
with  the  B  cell-specific  factor  NF-EM5  (Pip)  (8,  24). 
When a  PU. 1 expression construct lacking the PEST do- 
main  was  transfected  into  BMDM,  an  enhancement of 
macrophage proliferation similar to that obtained using the 
wild PU. 1 construction was  observed,  suggesting that the 
PEST domain was not important for this activity (Fig. 7 A). 
A  decrease  in M-CSF-dependent proliferation, however, 
was observed when a PU.1 construct containing the DNA- 
binding domain  (ETS  domain)  was  transfected  into  the 
cells  (Fig.  7  B).  The  decrease  in  proliferation  observed 
when the DNA-binding domain was used may be due to 
the  competiton  between  the  endogenous PU.1  and  the 
transfected DNA-binding  domain for a target sequence in a 
promoter or enhancer of a gene or genes involved in pro- 
liferation. Taken together, these data support the hypothe- 
sis that at least one of the functional activities of PU. 1 in 
macrophages is related to the control of genes involved in 
M-CSF-stimulated cell proliferation. 
The PU.1 transcription factor in routine macrophages is 
known to be phosphorylated on five serines that are con- 
sensus sites for casein kinase II (CK II) (9, and our unpub- 
lished results).  The  predicted serine CK  II  target  sites  in 
PU.1 were mutated to alanines and we examined whether 
the  mutations had  an affect  on the  ability of PU.1  trans- 
fected  into BMDM  to  stimulate proliferation. PU.1  with 
the  $132/133A  or  $148A  mutations was  as  active as  the 
wild-type protein in stimulating proliferation of BMDM 
(Fig.  7  B).  In contrast,  PU.1  protein carrying an alanine 
substitution at $41  or $45 not only failed to stimulate pro- 
liferation, but also lowered the basal level of proliferation. 
The effect of the $41/45A double mutation was about the 
same as either of the single mutations. It is therefore likely, 
at least in macrophages, that phosphorylation of amino ac- 
ids 41  and/or 45 results in the activation of a domain im- 
portant for the activity of PU. 1. 
Discussion 
The data presented here indicate that PU. 1 is involved in 
macrophage proliferation. The block in macrophage prolif- 
eration using either an antisense PU. 1 expression construct 
or  antisense  oligonucleotides suggests  that  PU.1  plays  a 
critical role in the proliferation of macrophages. The use of 
antisense oligonucleotides to  inhibit gene  expression  and 
cell  growth  and  development has  provided  new  insight 
into the functional importance of a  variety of genes  (45). 
Antisense ohgodeoxynucleotides of PU. 1 inhibit the prolif- 
eration of erythroleukemia cells induced by the retrovirus 
SFFV  (46).  In  this  model,  if the  provirus  integrates  up- 
stream  of the  PU.I  gene,  PU.1  is  overexpressed  and the 
cell loses its commitment to terminally differentiate and be- 
comes  immortal. A  reduction in the  expression of PU.1 
coincides with recommitment to the program of erythroid 
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tion  of erythroblasts  with  a  retroviral  vector  expressing 
PU.1  was  efficient  for  immortalization,  suggesting  that 
PU.1  perturbs  the pathway that controls the potential for 
proliferation in these cells (48). 
The enhancement of macrophage proliferation induced 
by the  transfection  of PU.1  appears to  be related  to  the 
presence of M-CSF  in the media.  This may explain why 
PU.1  is not effective in cell lines whose proliferation is in- 
dependent of growth factors. 
The effect of PU.1  protein seems to be specific because 
other ets family members such as ets-2 and fli-1 were inef- 
fective in stimulating proliferation. The Ets family consists 
of a large number of proteins that have sequence identity 
within  the  DNA-binding  domain,  and  all  bind  to  a  se- 
quence containing the core sequence 5'-GGAA/T-3' (43). 
Whereas  the  core  sequence  appears  to  be  necessary  for 
binding it is known that flanking sequences also influence 
the  binding  of specific Ets  family members to DNA  (44, 
and our unpublished  results).  This may be part of the ex- 
planation for why PU.1  has an effect on macrophage pro- 
liferation, but not ets-2 or fli-1. 
PU.1  functions in association with other factors (8,  10, 
19,  49,  50).  In  the  mouse,  K 3'  enhancer  for  example, 
PU.1  recruits a B  cell-restricted factor, NF-EM5  (Pip)  (8, 
24). The protein-protein interaction is mediated through a 
43--amino acid region with sequence homology to a PEST 
domain,  i.e.,  one that is rich in proline  (P),  glutamic acid 
(E),  serine  (S),  and threonine  (T), which  is susceptible to 
protease  degradation  (51).  The  PEST  sequence  does  not 
appear to have a role in the  enhancement of macrophage 
proliferation by PU.1.  However,  expression  of the  PU.1 
DNA-binding  domain  resulted in  a  reduced  proliferation 
of BMDM.  Dominant  negative  constructs  of the  PU.1 
DNA-binding domain have proven useful in demonstrat- 
ing the function of PU. 1 in regulating gene expression. A 
dominant negative expression construct of PU.1  in which 
aminos acids  133  to  the  end were  expressed was used to 
show that PU. 1 was needed for expression from the J chain 
gene promoter (12).  A dominant negative PU.1  expression 
construct  (amino  acids  160-266)  transfected  into  Ras- 
transformed NIH3T3 fibroblasts reverted the  transformed 
phenotype (52).  This latter result may be due to a general 
feature of the DNA-binding domains of ETS family mem- 
bers since dominant negative constructs of ets-1  and ets-2 
had the same effect. The finding that mutations at serine 41 
and 41/45 caused a lowering of  proliferation in BMDM sug- 
gests that this region plays an important role for this activity. 
The NH2-terminal halfofPU.1 is known to be responsible 
for the transactivation properties of PU. 1 (our unpublished 
results).  This may provide part of the  explanation for the 
results seen with the serine 41  and 41/45 mutations. 
The number of genes regulated by PU.1 that could mod- 
ulate macrophage proliferation in response to M-CSF is at 
present unknown. Because the enhancement of proliferation 
requires the presence of the growth factor M-CSF, one pos- 
sible candidate is the M-CSF receptor (c-fms), which is spe- 
cifically expressed in macrophages (3). Recently, it has been 
reported  that  PU.1  directs  the  expression  of the  M-CSF 
receptor (17,  42,  53).  PU.1  binds  to a specific site in the 
M-CSF  receptor promoter just  upstream from the  major 
transcription initiation site. Mutations at this site have been 
shown  to  eliminate  PU.1  binding  and  decrease promoter 
activity. PU. 1 transactivates a reporter construct containing 
the M-CSF promoter. These experiments were performed 
by cotransfection in cells that normally do not express PU. 1 
or the M-CSF receptor, with PU.1  cDNA and a reporter 
construct containing the M-CSF promoter (17).  It has also 
been  reported  that  ets-2  transactivates  the  proximal pro- 
moter of the M-CSF receptor (42, 53). In our experiments, 
ets-2  had  no  effect  on  M-CSF-dependent  macrophage 
proliferation. This may be due to an already high level of 
ets-2 expression in the cells (our unpublished results). 
PU. 1 is thought to regulate a number of other genes that 
could be involved in cell proliferation. For instance, PU.1 
binds the tumor suppressor protein p53 which represses cell 
proliferation (49).  The inhibition of an inhibitor could re- 
sult in  the  activation of proliferation.  In vitro,  PU.1  was 
also shown to interact with the general transcription factor 
TFIID (49).  PU.1  and PU.l-associated factor(s) could sta- 
bilize TFIID and allow assembly of the initiation complex 
of genes related to proliferation. However, the fact that en- 
hancement of macrophage proliferation is M-CSF or GM- 
CSF dependent probably rules out this possibility. 
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